Market Size and Overview
The North America leukemia therapeutics market reached US$ 2.9 billion in 2023 and is expected to reach US$ 6 billion by 2031, growing at a CAGR of 9.8% during the forecast period 2024-2031.
Leukemia is a blood cancer that occurs when the bone marrow produces abnormal white blood cells, also called blasts or leukemia cells. These abnormal cells can't fight infections and prevent the bone marrow from producing healthy red blood cells and platelets. Leukemia can spread to the lymph nodes, bloodstream, brain, spinal cord, and other parts of the body. If it spreads to the brain, symptoms may include headaches, seizures, balance problems, or vision problems.
If it spreads to the lymph nodes in the chest, symptoms may include breathing problems and chest pain. For the treatment of lymphoma various therapies such as targeted therapy, chemotherapy, immunotherapy, CAR T cell therapy, stem cell transplantation, and radiation therapy are used depending upon the type of leukemia and condition of the leukemia.
Market Scope
| Metrics | Details |
| CAGR | 9.8% |
| Market Size | 2022-2031 |
| Market Estimation Forecast Period | 2024-2031 |
| Revenue Units | Value (US$ Mn) |
| Segments Covered | Cancer Type, Therapy, and End-User |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter's Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights. |
For more details on this report - Request for Sample
Market Dynamics: Drivers
Increasing prevalence of leukemia
The demand for the leukemia therapeutics market is driven by multiple factors. For instance, according to the according to the National Cancer Institute, in the US, the estimated new leukemia cases in 2024 are 62,770. The new leukemia cases contribute 3.1% of all new cancer cases. The estimated number of deaths due to leukemia in 2024 are 23,670. The deaths due to leukemia contribute 3.9% of all cancer deaths.
Moreover according to the Leukemia & Lymphoma Society, Approximately every 3 minutes, one person in the US is diagnosed with leukemia, lymphoma or myeloma. An estimated combined total of 184,720 people in the US are expected to be diagnosed with leukemia, lymphoma or myeloma in 2023. New cases of leukemia, lymphoma and myeloma are expected to account for 9.4 percent of the estimated 1,958,310 new cancer cases that will be diagnosed in the US in 2023.
An estimated 1,629,474 people in the United States (US) are living with or in remission from leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS) or myeloproliferative neoplasms (MPNs). Approximately every 9 minutes, someone in the US dies from a blood cancer. This statistic represents approximately 157 people each day or more than six people every hour.
Leukemia, lymphoma and myeloma are expected to cause the deaths of an estimated 57,380 people in the US in 2023. These diseases are expected to account for 9.4 percent of the deaths from cancer in 2023, based on the estimated total of 609,820 cancer deaths. In 2023, an estimated 21,080 members of the US population are expected to die from lymphoma (900 HL and
20,180 NHL).
Restraints
Factors such as high costs associated with the treatment and stringent regulatory requirements for the approval of new treatments are expected to hamper the market. For instance, according to the National Institute of Health, the cumulative drug cost for 1 year of alemtuzumab which is used in the treatment of chronic leukemia, is US$ 70,000. Higher costs of drugs which affect the drug affordability of many people are one of the aspects that acts as a restraint to the North America leukemia therapeutics market.
Market Segment Analysis
The North America leukemia therapeutics market is segmented based on cancer type, therapy, end-user, and region.
The targeted therapy accounted for approximately 49.6% of the North America leukemia therapeutics market share.
The targeted therapy segment is expected to hold the largest market share over the forecast period. In this segment, the development of government regulation, and rising funds for private manufacturers for clinical trials would drive this market.
Targeted therapy drugs are the first line of treatment for certain types of leukemia. These medicines find and target specific proteins or changes in cells that cause leukemia. Unlike chemotherapy (which affects healthy and diseased cells), targeted therapy focuses only on the cell changes that cause the cancer. The drugs cause minimal, if any, damage to healthy cells. There are different types of targeted therapy drugs for leukemia. The lab-made drugs can find specific substances in leukemia cells, such as proteins or genetic (DNA) changes. The drugs then damage or destroy the diseased cells.
For instance, in January 2023, the Food and Drug Administration approved the drug zanubrutinib (brukinsa) for the targeted treatment of people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). At 2 years after starting treatment, more than 78% of patients receiving zanubrutinib were alive with no growth of their cancer, compared with 66% of patients taking ibrutinib. Zanubrutinib was particularly effective in people whose cancer had genetic mutations that typically signal a poorer prognosis.
Market Segmentation
By Cancer Type
- Chronic Myeloid Leukemia
- Acute Lymphocytic Leukemia
- Acute Myeloid Leukemia
- Chronic Lymphocytic Leukemia
- Others
By Therapy
- Targeted Therapy
- Bosutinib
- Venetoclax
- Chemotherapy
- Rituximab
- Dasatinib
- Immunotherapy
- Ofatumumab
- Brexucabtagene autoleucel
- Others
By End-User
- Hospitals and Clinics
- Cancer Centers
- Ambulatory Surgical Centers
- Others
Competitive Landscape
The major players in the North America leukemia therapeutics market include Hoffmann-La Roche Ltd, GlaxoSmithKline Pharmaceuticals Limited, Novartis AG, Bristol-Myers Squibb, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd, AstraZeneca, Abbott, Novo Nordisk A/S, and Pfizer Inc. among others.
Key Developments
- In July 2023, the US Food and Drug Administration (FDA) approved quizartinib (Vanflyta) combined with chemotherapy as part of the initial treatment of people with AML that has a specific change in a gene called FLT3.
- In February 2024, the U.S. Food and Drug Administration approved a bi-weekly dose of Johnson & Johnson's blood cancer therapy Tecvayli. The approval allows the therapy to be used in a reduced dosing of 1.5 milligrams per kilogram every two weeks, in patients who have achieved and maintained a complete response or better for a minimum of six months.
Why Purchase the Report?
- To visualize the North America leukemia therapeutics market segmentation based on cancer type, therapy, and end-user, as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development
- Excel data sheet with numerous data points of North America leukemia therapeutics market level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping is available in Excel consisting of key products of all the major players.
The North America leukemia therapeutics market report would provide approximately 51 tables, 54 figures, and 181 Pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
